Data Presented Shows Minimally Invasive RezumŪ System Provides Significant LUTS Relief in Obese Men While Preserving Sexual Function

Tuesday, May 16, 2017 Sexual Health News
Email Print This Page Comment bookmark
Font : A-A+

Presentation by Dr. Nikhil Gupta Named Best Abstract During 2017 American Urological Association Annual Meeting

MAPLE GROVE, Minn., May 16, 2017 /PRNewswire/ -- NxThera, Inc., a medical device company pioneering the application

of its convective radiofrequency thermotherapy to treat endourological conditions, announced the presentation of data demonstrating the effectiveness of its minimally invasive Rez?mŪ System to treat obese men suffering from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) at the 2017 American Urological Association (AUA) Annual Meeting in Boston. The AUA also named this presentation as a Best Abstract out of nearly 3,000 abstracts presented during the conference.

The abstract, entitled, "Convective Radiofrequency Water Vapor Energy Ablation (Rez?m) Effectively Treats Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement Regardless of Obesity While Preserving Erectile and Ejaculatory Function," was presented by Dr. Nikhil Gupta, urologist at Southern Illinois University School of Medicine, and a fellow of Dr. Kevin McVary. The data presented by Dr. Gupta demonstrated that obese men, defined as having a body mass index (BMI) of 30 or more, enrolled in the study experienced similar improvements in International Prostate Symptom Score (IPSS), including both urinary storage and voiding domains, after a BPH procedure with the Rez?m System as compared to non­obese subjects. Obese subjects were more likely to have severe erectile dysfunction, but experienced a similar rate of minimal clinically important difference (MCID) and improvement in ejaculatory bother scores as those experienced by the non-obese subjects.

"Obesity is one of the strongest risk factors for the development of BPH and male LUTS. Additionally, in nearly all known treatments of male LUTS, whether traditional surgery or medical therapy, obesity is strongly associated with a reduced response to therapy and less improvement in urinary symptoms," Dr. Gupta said. "The results of this trial indicate that Rez?m is a promising, minimally invasive therapy for LUTS due to BPH, with the potential for long-term benefit, and the treatment effect of Rez?m is not dampened by obesity."

The Rez?m System uses radiofrequency current to create thermal energy that is convectively delivered to obstructive prostate tissue through targeted, precise treatments. The thermal energy ablates the tissue that causes BPH, which is resorbed by the body's immune system to alleviate the symptoms of BPH and improve patients' quality of life and ability to urinate.

In the Rez?m clinical study, 66 out of 196 (34 percent) patients were clinically obese. The controlled trial was conducted across 15 centers in the United States and the data demonstrated that obese patients who underwent treatment with the Rez?m System had similar improvements in IPSS and retained sexual function as reported via International Index of Erectile Dysfunction (IIEF-15) and Male Sexual Health Questionnaire for Ejaculatory Function (MSHQ-EjF) as compared to non-obese patients.

"As obesity continues to be a prominent factor in the prevalence of BPH, we're thrilled to provide urologists and their patients with a first-line BPH treatment option that is minimally invasive and equally effective in treating both obese and non-obese men, while preserving sexual function in both patient populations," said Bob Paulson, president and CEO of NxThera. "The results of this study continue to underscore the versatility of the Rez?m System, with capability to effectively treat the obstructive prostate tissue that causes BPH, including hyperplasia of the central zone."

For more information about the Rez?m System, visit www.Rez?  

About NxTheraNxThera pioneered its convective radiofrequency thermotherapy platform technology to treat a variety of endourological conditions, beginning with BPH. The company is furthering the application of its technology platform through advanced research and development, and clinical studies, targeting the treatment of prostate cancer and kidney cancer. NxThera's FDA-cleared Rez?m System to treat BPH is a next-generation transurethral needle ablation system that uses radiofrequency to create thermal energy that is convectively delivered to obstructive prostate tissue in targeted, precise treatments, with minimal discomfort. Treatments with the Rez?m System improve the bothersome symptoms of BPH, including urine flow and quality of life. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.Rez?


To view the original version on PR Newswire, visit:

SOURCE NxThera, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store